NCT07648069 — Sun Yat-sen University neoantigen vaccine trial
Tumor Neoantigen Vaccine SarVac Combined With Tumor Specific Lymphocyte Reinfusion in the Treatment of Advanced Sarcoma
Registry record
| Registry ID | NCT07648069 ↗ |
|---|---|
| Lead sponsor | Sun Yat-sen University |
| Collaborators | — |
| Phase | Phase 1 |
| Status | Recruiting |
| Indication | Soft Tissue Sarcoma (STS), Osteosarcoma |
| Enrollment | 16 participants (target) |
| Start date | 2024-09-03 |
| Primary completion | 2026-12-31 (est.) |
| Last registry update | 15 Jun 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT07648069), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
No modality, tumor or player hub covers this study yet. Browse the field map for the axes the daily brief does track.
Related trials
FAQ
What phase is NCT07648069?
NCT07648069 (Tumor Neoantigen Vaccine SarVac Combined With Tumor Specific Lymphocyte Reinfusion in the Treatment of Advanced Sarcoma) is registered on ClinicalTrials.gov as Phase 1, sponsored by Sun Yat-sen University.
Is NCT07648069 recruiting?
As of the 2026-06-15 registry update, NCT07648069 is listed as "Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT07648069?
The lead sponsor is Sun Yat-sen University.
What condition does NCT07648069 study?
The registered conditions are Soft Tissue Sarcoma (STS), Osteosarcoma. Primary completion is listed as 2026-12-31 (estimated).
Are results available for NCT07648069?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT07648069.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.